{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:52:37Z","timestamp":1787755957185,"version":"build-2784847793"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.lungcan.2018.05.030","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T05:57:41Z","timestamp":1527832661000},"page":"83-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Management of co-existent tuberculosis and lung cancer"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4499-5284","authenticated-orcid":false,"given":"James Chung-man","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chiu","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.05.030_bib0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/aje\/kws151","article-title":"Previous lung diseases and lung cancer risk: a pooled analysis from the international lung cancer consortium","volume":"176","author":"Brenner","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0010","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/ijc.24636","article-title":"Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review","volume":"125","author":"Liang","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/JTO.0b013e3181fb4fcc","article-title":"Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study","volume":"6","author":"Yu YH","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5588\/ijtld.12.0816","article-title":"Tuberculosis is associated with increased lung cancer mortality","volume":"17","author":"Leung","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.201402-0338OC","article-title":"Is previous respiratory disease a risk factor for lung cancer?","volume":"190","author":"Denholm","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0030","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1001\/archinte.168.21.2326","article-title":"Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"168","author":"Yu YY","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1534735403256332","article-title":"Inflammation as cause for scar cancers of the lung","volume":"2","author":"Ardies","year":"2003","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0040","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3816\/CLC.2003.n.021","article-title":"The potential contributions of chronic inflammation to lung carcinogenesis","volume":"5","author":"Ballaz","year":"2003","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood.V76.4.655.655","article-title":"Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis","volume":"76","author":"Weitzman","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0055","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1200\/JCO.2006.07.1381","article-title":"C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study","volume":"24","author":"Siemes","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0060","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/onc.2009.32","article-title":"Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control","volume":"28","author":"Nalbandian","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2014.12.007","article-title":"Imaging in tuberculosis","volume":"32","author":"Skoura","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0070","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MCP.0000000000000043","article-title":"Advances in imaging of tuberculosis: the role of (1)(8)F-FDG PET and PET\/ CT","volume":"20","author":"Vorster","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0075","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3892\/etm.2017.4737","article-title":"Asymptomatic pulmonary tuberculosis mimicking lung cancer on imaging: a retrospective study","volume":"14","author":"Lang","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12149-015-1047-6","article-title":"(18)F-FDG and (18)F-FLT PET\/CT imaging in the characterization of mediastinal lymph nodes","volume":"30","author":"Rayamajhi","year":"2016","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7196\/SAMJ.8357","article-title":"Integrated positron emission tomography\/computed tomography for evaluation of mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic area: a 5-year prospective observational study","volume":"105","author":"Shaw","year":"2015","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0090","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12149-015-0958-6","article-title":"Update on nodal staging in non-small cell lung cancer with integrated positron emission tomography\/computed tomography: a meta-analysis","volume":"29","author":"Pak","year":"2015","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009519.pub2","article-title":"PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer","author":"Schmidt-Hansen","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0100","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1016\/j.ejrad.2012.02.007","article-title":"Meta-analysis study of lymph node staging by 18 F-FDG PET\/CT scan in non-small cell lung cancer: comparison of TB and non-TB endemic regions","volume":"81","author":"Liao","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0105","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/cncr.22518","article-title":"Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET\/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients","volume":"109","author":"Kim","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1440-1843.2006.00789.x","article-title":"Positron emission tomography with CT in the evaluation of non-small cell lung cancer in populations with a high prevalence of tuberculosis","volume":"11","author":"Low","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0115","first-page":"20","article-title":"Endobronchial ultrasound-guided transbronchial needle aspiration in lung cancer: the first experience in Hong Kong","volume":"19","author":"Wong","year":"2013","journal-title":"Hong Kong Med. J."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0120","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.12.0010","article-title":"(18)F-FDG PET\/CT in tuberculosis: an early non-invasive marker of therapeutic response","volume":"16","author":"Martinez","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0125","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1200\/JCO.2012.46.0667","article-title":"Diagnostic and treatment dilemma of dual pathology of lung cancer and disseminated tuberculosis","volume":"32","author":"Shetty","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0130","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2967\/jnumed.115.167924","article-title":"Comparing the diagnostic potential of 68Ga-alfatide II and 18F-FDG in differentiating between non-small cell lung cancer and tuberculosis","volume":"57","author":"Kang","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3348\/kjr.2001.2.3.138","article-title":"Coexisting bronchogenic carcinoma and pulmonary tuberculosis in the same lobe: radiologic findings and clinical significance","volume":"2","author":"Kim","year":"2001","journal-title":"Korean J. Radiol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0140","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0150","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0165","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0170","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0175","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive Non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0180","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0185","article-title":"Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0190","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0195","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0205","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0210","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1378\/chest.128.4.2218","article-title":"Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy","volume":"128","author":"Kim","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0215","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0220","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jtho.2016.10.008","article-title":"Anti-PD-1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Reungwetwattana","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0225","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0230","first-page":"1226","article-title":"The diagnosis and misdiagnosis of tuberculosis","volume":"12","author":"Davies","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0235","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0040-2016","article-title":"Impact of the GeneXpert MTB\/RIF technology on tuberculosis control","volume":"5","author":"Stevens","year":"2017","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0240","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.12659\/MSM.897638","article-title":"Does every necrotizing granulomatous inflammation identified by NSCLC resection material require treatment?","volume":"22","author":"Yakar","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0245","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/jclinpath-2016-203868","article-title":"Significance of coexistent granulomatous inflammation and lung cancer","volume":"70","author":"Dagaonkar","year":"2017","journal-title":"J. Clin. Pathol"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0250","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.lungcan.2009.03.001","article-title":"Sarcoidal reactions in regional lymph nodes of patients with non-small cell lung cancer: incidence and implications for minimally invasive staging with endobronchial ultrasound","volume":"66","author":"Steinfort","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0255","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1378\/chest.09-0472","article-title":"Sarcoidosis or sarcoid reaction?","volume":"136","author":"Marruchella","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0260","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1440-1843.2009.01598.x","article-title":"Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis","volume":"14","author":"Wang","year":"2009","journal-title":"Respirology"},{"key":"10.1016\/j.lungcan.2018.05.030_bib0265","first-page":"432","article-title":"Factors associated with time to sputum smear conversion in active pulmonary tuberculosis","volume":"7","author":"Dominguez-Castellano","year":"2003","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-7819-5-22","article-title":"Lung cancer in patients with tuberculosis","volume":"5","author":"Cicenas","year":"2007","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0275","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1055\/s-0036-1583167","article-title":"Management and surgical outcomes of concurrent tuberculosis and lung cancer","volume":"65","author":"Evman","year":"2017","journal-title":"Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2018.05.030_bib0280","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4049\/jimmunol.181.1.116","article-title":"Programmed death (PD)-1:PD-ligand 1\/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis","volume":"181","author":"Jurado","year":"2008","journal-title":"J. Immunol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218304094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218304094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:28:31Z","timestamp":1759235311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218304094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":56,"alternative-id":["S0169500218304094"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.05.030","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of co-existent tuberculosis and lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}